Verve Therapeutics

About Us
Why Cardiovascular Disease
Our Approach

Our Pipeline
Culture & Careers
Investors

How a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times

Post navigation

Previous PostPrevious COVID-19 testing to keep employees safe

Next PostNext The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them

Verve Therapeutics, Inc., all rights reserved

Contact Us
Privacy Policy

Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
Contact Us